GLS-010, a novel fully human anti-PD-1 mAb in patients with advanced tumor: Preliminary results of a Phase Ib clinical trial

被引：0

作者：

Shen, Lin ^{[1
]}

Gong, Jifang ^{[1
]}

Song, Yuqin ^{[2
]}

Ye, Dingwei ^{[3
]}

Lu, Zhihao ^{[1
]}

Wang, Siyang ^{[4
]}

Peng, Peijian ^{[4
]}

Chen, Jianhua ^{[5
]}

Jiang, Ou ^{[6
]}

Zhang, Guojun ^{[7
]}

Bai, Yuxian ^{[8
]}

Pan, Jianji ^{[9
]}

Ma, Chunguang ^{[3
]}

Chen, Li ^{[10
]}

Ba, Yi ^{[11
]}

Li, Qi ^{[12
]}

Lu, Ping ^{[13
]}

Zhang, Lingli ^{[14
]}

Yin, Xianli ^{[15
]}

Gu, Shanzhi ^{[15
]}

Zhang, Huilai ^{[16
]}

Su, Hang ^{[17
]}

Jiang, Yongsheng ^{[18
,19
]}

Cao, Bangwei ^{[20
]}

Han, Weiqing ^{[15
]}

Sun, Yan ^{[21
]}

Zhang, Feng ^{[22
]}

Ouyang, Weiwei ^{[23
]}

Dong, Haiying ^{[24
]}

Guo, Jianming ^{[25
]}

Guo, Yabing ^{[26
]}

Xu, Chongyuan ^{[26
]}

Qi, Junyuan ^{[27
]}

Wang, Li ^{[28
]}

Lv, Jun ^{[29
]}

Wang, Xiang ^{[12
]}

Chen, Chris ^{[30
]}

Li, Jing ^{[30
]}

Zheng, Yong ^{[30
]}

Jin, Ge ^{[31
]}

Yang, Yining ^{[31
]}

Zhao, Guodong ^{[31
]}

Yang, Fan ^{[32
]}

Xu, Kehui ^{[32
]}

Liang, Xiangying ^{[32
]}

Pan, Zhaoyang ^{[32
]}

Meng, Haijin ^{[32
]}

机构：

[1] Peking Univ Canc Hosp & Inst, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[2] Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing, Beijing, Peoples R China

[3] Fudan Univ, Shanghai Canc Ctr, Shanghai Med Coll, Dept Urol, Shanghai, Peoples R China

[4] Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China

[5] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp,Thorac Med Dept 1, Changsha, Peoples R China

[6] Second Gen Hosp Neijiang City, Neijiang, Peoples R China

[7] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China

[8] Harbin Med Univ, Canc Hosp, Haerbin, Peoples R China

[9] Fujian Prov Canc Hosp, Fuzhou, Peoples R China

[10] Nanchang Univ, Affiliated Hosp 5, Nanchang, Jiangxi, Peoples R China

[11] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China

[12] Shanghai Gen Hosp, Shanghai, Peoples R China

[13] Xinxiang Med Sch, Affiliated Hosp 1, Xinxiang, Henan, Peoples R China

[14] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Wuhan, Peoples R China

[15] Cent South Univ, Hunan Canc Hosp, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China

[16] Tianjin Med Univ Canc Inst & Hosp, Lymphoma Dept, Tianjin, Peoples R China

[17] Peoples Liberat Army Gen Hosp, Med Ctr 5, Beijing, Peoples R China

[18] Huazhong Univ Sci & Technol, Tongji Hosp, Wuhan, Peoples R China

[19] Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan, Peoples R China

[20] Capital Med Univ, Beijing Friendship Hosp, Beijing, Peoples R China

[21] Peking Univ Canc Hosp & Inst, Dept Oncol Radiotherapy, Beijing, Peoples R China

[22] Bengbu Med Sch, Affiliated Hosp 1, Bengbu, Peoples R China

[23] Guizhou Canc Hosp, Guiyang, Peoples R China

[24] Zhengjiang Prov Peoples Hosp, Hangzhou Med Coll, Peoples Hosp, Hangzhou, Peoples R China

[25] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China

[26] Nanfang Hosp, Southern Med Sch, Affiliated Hosp 1, Guangzhou, Peoples R China

[27] Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[28] Jiangsu Prov Hosp, Nanjing, Peoples R China

[29] Capital Med Univ, Beijing Youan Hosp, Beijing, Peoples R China

[30] WuXi Biol Shanghai Co Ltd, Shanghai, Peoples R China

[31] GloriousMed Technol Co Ltd, Beijing, Peoples R China

[32] Guangzhou Gloria Biosci Co Ltd, Beijing, Peoples R China

来源：

CANCER RESEARCH | 2020年 / 80卷 / 16期

关键词：

D O I：

10.1158/1538-7445.AM2020-3275

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

3275

引用

页数：4

共 50 条

[1] Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial
Song, Yuqin
Zhu, Jun
Lin, Ningjing
Zhang, Mingzhi
Bai, Hai
Liu, Hui
Cui, Jie
Ke, Xiaoyan
Zhang, Huilai
Liu, Lihong
Yan, Dongmei
Jiang, Yongsheng
Zang, Aimin
Qi, Junyuan
Wang, Li
Liu, Zhuogang
Xu, Bing
Zhang, Ying
Zhang, Zhihui
Meng, Haijin
BLOOD, 2020, 136
[2] A novel recombinant human anti-PD-1 monoclonal antibody GLS-010 in patients with advanced cancer: Result of a phase Ia clinical trial
Shen, L.
Gong, J.
Xu, Y.
Zhang, X.
Peng, Z.
Qi, C.
Li, G.
Meng, H.
Liu, Z.
Wang, H.
Chen, C.
Li, J.
Zheng, Y.
Lee, J.
Zhang, Y.
Zhang, Q.
ANNALS OF ONCOLOGY, 2018, 29
[3] Gls-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin lymphoma: Preliminary impressive result of a phase II clinical trial.
Song, Yuqin
Zhu, Jun
Lin, Ningjing
Zhang, Mingzhi
Bai, Hai
Liu, Hui
Cui, Jie
Ke, Xiaoyan
Zhang, Huilai
Liu, Lihong
Yan, Dongmei
Jiang, Yongsheng
Zang, Aimin
Qi, Junyuan
Wang, Li
Liu, Zhuogang
Xu, Bing
Zhang, Ying
Zhang, Zhihui
Meng, Haijin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[4] GLS-010, a novel anti-PD-1 mAb in Chinese patients with relapsed or refractory classical Hodgkin's lymphoma: Preliminary result of a phase II clinical trial.
Song, Yuqin
Zhu, Jun
Lin, Ningning
Zhang, Chen
Zhang, Mingzhi
Bai, Hai
Cui, Jie
Liu, Hui
Ke, Xiaoyan
Jiang, Yongsheng
Zhang, Zhihui
Zhang, Ying
Liu, Lihong
Zang, Aimin
Chen, Chris
Li, Jing
Du, Hong
Meng, Baotong
Xu, Kehui
Meng, Haijin
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer
Lou, Beilei
Wei, Hua
Yang, Fang
Wang, Shicong
Yang, Baotian
Zheng, Yong
Zhu, Jiman
Yan, Shaoyu
FRONTIERS IN ONCOLOGY, 2021, 11
[6] G1s-010, a novel anti-PD-1 mAb in Chinese advanced gastrointestinal tumor: Result of a phase Ib clinical trial.
Lin, Shen
Gong, Jifang
Xu, Yingying
Zhang, Xiaotian
Peng, Zhi
Qi, Changsong
Li, Guochun
Meng, Haijin
Liu, Zhen
Wang, Hui
Chen, Chris
Li, Jing
Zheng, Yong
Lee, Johnathan
Zhang, Yan
Zhang, Qiang
Jin, Ge
Yang, Yining
Zhao, Guodong
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[7] GLS-010 (ZIMBERELIMAB), A NOVEL FULLY HUMAN ANTI-PD-1 MAB IN CHINESE PATIENTS WITH RECURRENT/METASTATIC CERVICAL CANCER: RESULTS FROM A MULTICENTER, OPEN-LABEL, SINGLE-ARM PHASE II TRIAL
Wu, X.
Xia, L.
Zhou, Q.
Zhu, J.
Wang, K.
Chen, J.
Huang, Y.
Kurb, G.
Chang, B.
Zhao, W.
Wang, X.
Yang, Y.
Lin, Z.
Luo, X.
Lou, G.
Wang, C.
Wang, J.
Meng, H.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A147 - A147
[8] Preclinical characterization of GLS-010 (AB122): A fully humanized clinical-stage anti-PD-1 antibody
Tan, Joanne B.
Chen, Chris
Chen, Kai
Li, Guochun
Li, Jing
Liu, Jieying
Singh, Hema
Wang, Guoyong
Yang, Baotian
Zhang, Kristin
Zhao, Xiaoning
Zheng, Yong
CANCER RESEARCH, 2018, 78 (13)
[9] Gls-010, a novel anti-PD-1 mAb in Chinese patients with recurrent or metastatic cervical cancer: Results from a multicenter, open-label and single-arm phase II trial.
Wu, Xiaohua
Xia, Lingfang
Zhou, Qi
Zhu, Jianqing
Wang, Ke
Chen, Jie
Huang, Yi
Kurb, Gulina
Chang, Baoping
Zhao, Weidong
Wang, Xia
Yang, Yingjie
Lin, Zhongqiu
Luo, Xiaoyong
Lou, Ge
Wang, Chunyan
Wang, Jing
Meng, Haijin
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphoma
Liu, Dan
Ma, Chunguang
Lu, Ping
Gong, Jifang
Ye, Dingwei
Wang, Siyang
Peng, Peijian
Bai, Yuxian
Song, Yuqin
Chen, Jianhua
Jiang, Ou
Zhang, Guojun
Ba, Yi
Chen, Li
Pan, Jianji
Li, Qi
Zhang, Liling
Gu, Shanzhi
Yin, Xianli
Cao, Bangwei
Han, Weiqing
Dong, Haiying
Guo, Jianming
Zhang, Huilai
Su, Hang
Jiang, Yongsheng
Ouyang, Weiwei
Ma, Lulin
Sun, Yan
Zhang, Feng
Lv, Jun
Guo, Yabing
Xu, Chongyuan
Qi, Junyuan
Wang, Li
Wang, Xiang
Liu, Zhen
Shen, Lin
EUROPEAN JOURNAL OF CANCER, 2021, 148 : 1 - 13

← 1 2 3 4 5 →